Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MIRM
SellHot AirMirum Pharmaceuticals, Inc. · Healthcare · United States · $5.9B · Avg Vol: $62M/d
COMPANY DESCRIPTION
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare liver diseases, primarily targeting cholestatic liver conditions in pediatric and adult patients. The company's pipeline and approved product (Livmarli) address significant unmet medical needs, leveraging a deep understanding of bile acid biology. Mirum benefits from its specialized focus and orphan drug designations, providing market exclusivity and a clear path to serving specific patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.1M | 186.4M | 336.9M | 521.3M | 89.1% | 618.1M | 696.6M | 816.0M | 25.1% |
| EPS | -4.01 | -3.94 | -1.85 | -0.47 | — | -14.08 | -15.14 | — | — |
| Shares | 37.0M | 46.7M | 48.3M | 51.9M | +40.4% | 61.0M | — | — | — |
| Debt | 2.2M | 308.1M | 317.8M | 319.5M | 426.6% | 762.9M | — | — | — |
| Equity | 142.0M | 248.7M | 225.6M | 314.7M | 30.4% | — | — | — | — |
| Op CF | -120.1M | -70.9M | 10.3M | 55.8M | 440.7% | -227.3M | — | — | — |
| Inv CF | 7.7M | -107.2M | -90.1M | -24.0M | — | — | — | — | — |
| Fin CF | 109.1M | 336.6M | 17.7M | 40.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MIRM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc.(you) | $5.9B | 30 | Sell |
| PTCT | PTC Therapeutics, Inc. | $5.8B | 32 | Sell |
| ORKA | Oruka Therapeutics, Inc. | $6.0B | 27 | Sell |
| DNTH | Dianthus Therapeutics, Inc. | $5.9B | 23 | Sell |
| EWTX | Edgewise Therapeutics, Inc. | $4.6B | 28 | Sell |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.4B | 33 | Sell |
| LEGN | Legend Biotech Corporation | $3.9B | 30 | Sell |
| RLAY | Relay Therapeutics, Inc. | $4.1B | 28 | Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| PRAX | Praxis Precision Medicines, Inc. | $9.6B | 31 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%